Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report released on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

Evogene stock opened at $1.57 on Wednesday. The firm’s fifty day moving average price is $1.59 and its 200 day moving average price is $2.67. The company has a market capitalization of $8.43 million, a price-to-earnings ratio of -0.35 and a beta of 1.30. Evogene has a 12-month low of $1.20 and a 12-month high of $10.40.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.